Loading stock data…
MCK
$811.99-2.05 (-0.25%)
Market OpenUpdated 9:56 AM EDT
McKesson Corporation provides healthcare services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
McKesson Corporation in the Healthcare sector is trading at $811.99. The stock is currently 19% below its 52-week high of $999.00, remaining 0.0% below its 200-day moving average. Technical signals show oversold RSI of 21 and bearish MACD signal, explaining why MCK maintains its current current market pressure. The Whystock Score of 80/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 21) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$811.99
Potential Downside
228.4%
Whystock Fair Value$-1042.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$990.87+22.0%
Range$860.00 – $1107
Fundamentals
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Phar...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$102.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.95
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Strong income play. Yield provides a meaningful total return floor.
39.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-243.76%
Volume
Today's trading volume
57,170
Recent News
DEI Programs Are Dwindling But the Trump Administration Isn't Done
(Bloomberg) -- After a remarkably successful effort to extinguish diversity, equity and inclusion programs at US employers, federal officials are stepping up their push against corporate America’s remaining DEI initiatives.Most Read from BloombergBeijing Tells China Firms to Ignore US Sanctions on RefinersSupertanker Appears to Have Crossed the Strait of HormuzFormer NYC Mayor Giuliani in Critical Condition, Trump SaysWorld’s Largest Container Carrier Plans Route Avoiding HormuzPhilippines Says
Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
William Blair Starts McKesson (MCK) at Outperform, Sees Durable Competitive Moat
McKesson Corporation (NYSE:MCK) is included among the 10 Best Large Cap Dividend Growth Stocks to Invest in. On April 28, William Blair initiated coverage of McKesson Corporation (NYSE:MCK) with an Outperform rating. The company has a “durable competitive moat” with specialty-led growth upside, the analyst tells investors in a research note. The firm believes McKesson […]
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
April 30 Reuters) - Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals